Signal from the log
Khartis Therapeutics, Inc.
50 M$ · Series B · United States · Biotech
Khartis sort de l'ombre avec 95 M$ et un pari oral sur la maladie oculaire thyroïdienne, un inhibiteur sélectif de IGF-1R en comprimé là où le standard actuel se perfuse. Siège à San Diego, incubée chez Foresite Labs.
Spotted
Announced on , logged by the watch of 13 August 2026.
- Operation
- Funding round
- Announced amount
- 50 M$
- Stage
- Series B
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
The investors
Led by Forge Life Science Partners , with Longwood Fund , Alexandria Venture Investments
Provenance
Source divenewsletter,endpoints
Logged on 13 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.